CANF

Can-Fite BioPharma
CANF

Upgrade to unlock
Buy
Hold
Sell

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
Avg. target
$6.75
1,757% upside
High target

2 analyst ratings

positive
0  neutral
0%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
D. Boral Capital
D. Boral Capital
Jason Kolbert
17% 1-yr CANF win rate
18 Nov ‘25 14 days ago
HC Wainwright & Co
HC Wainwright & Co
Swayampakula Ramakanth
0% 1-yr CANF win rate
4 Nov ‘25 28 days ago